{"id":"https://openalex.org/W7225743259","doi":"https://doi.org/10.25251/rdbfq523","title":"Efficacy of Tralokinumab in a Patient with Atopic Dermatitis Experiencing Loss of Response to Dupilumab: A Case Report","display_name":"Efficacy of Tralokinumab in a Patient with Atopic Dermatitis Experiencing Loss of Response to Dupilumab: A Case Report","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225743259","doi":"https://doi.org/10.25251/rdbfq523"},"language":"en","primary_location":{"id":"doi:10.25251/rdbfq523","doi":"https://doi.org/10.25251/rdbfq523","is_oa":true,"landing_page_url":"https://doi.org/10.25251/rdbfq523","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.25251/rdbfq523","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040993844","display_name":"Amy McDowell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amy McDowell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161404260","display_name":"Omar Daabies","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Omar Daabies","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161393576","display_name":"Joanna O\u2019Campo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joanna O\u2019Campo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161403318","display_name":"Nicole Surman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicole Surman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161385103","display_name":"Lindsey Rae Andrade","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lindsey Rae Andrade","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5064254265","display_name":"Cynthia Trickett","orcid":"https://orcid.org/0009-0008-9394-3820","observed_orcids":["https://orcid.org/0009-0008-9394-3820"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cynthia Trickett","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"6","first_page":"3539","last_page":"3542"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C2779824493","wikidata":"https://www.wikidata.org/wiki/Q5315925","display_name":"Dupilumab","level":3,"score":0.9438999891281128},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9199000000953674},{"id":"https://openalex.org/C2778329239","wikidata":"https://www.wikidata.org/wiki/Q268667","display_name":"Atopic dermatitis","level":2,"score":0.8004999756813049},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.6449999809265137},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5138999819755554},{"id":"https://openalex.org/C2780699399","wikidata":"https://www.wikidata.org/wiki/Q20708049","display_name":"Eczema Area and Severity Index","level":3,"score":0.4812999963760376},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.43849998712539673},{"id":"https://openalex.org/C2780194698","wikidata":"https://www.wikidata.org/wiki/Q6005429","display_name":"Immune dysregulation","level":3,"score":0.3952000141143799},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.32659998536109924},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3183000087738037},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.28870001435279846},{"id":"https://openalex.org/C205545832","wikidata":"https://www.wikidata.org/wiki/Q17156455","display_name":"Young adult","level":2,"score":0.27880001068115234},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.27720001339912415},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2768000066280365},{"id":"https://openalex.org/C2776360568","wikidata":"https://www.wikidata.org/wiki/Q2697787","display_name":"Hair loss","level":2,"score":0.2685999870300293},{"id":"https://openalex.org/C207480886","wikidata":"https://www.wikidata.org/wiki/Q42982","display_name":"Allergy","level":2,"score":0.26820001006126404},{"id":"https://openalex.org/C2780648854","wikidata":"https://www.wikidata.org/wiki/Q2745824","display_name":"Immunopathology","level":2,"score":0.26019999384880066},{"id":"https://openalex.org/C128057223","wikidata":"https://www.wikidata.org/wiki/Q420566","display_name":"Calcineurin","level":3,"score":0.25450000166893005},{"id":"https://openalex.org/C30036603","wikidata":"https://www.wikidata.org/wiki/Q17125150","display_name":"Severity of illness","level":2,"score":0.2517000138759613}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.25251/rdbfq523","doi":"https://doi.org/10.25251/rdbfq523","is_oa":true,"landing_page_url":"https://doi.org/10.25251/rdbfq523","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.25251/rdbfq523","doi":"https://doi.org/10.25251/rdbfq523","is_oa":true,"landing_page_url":"https://doi.org/10.25251/rdbfq523","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W2524051065","https://openalex.org/W2995377367","https://openalex.org/W3090227268","https://openalex.org/W3091046625","https://openalex.org/W4210685488","https://openalex.org/W4388454963","https://openalex.org/W4407353569","https://openalex.org/W4409574415","https://openalex.org/W4414537613","https://openalex.org/W4417037251"],"related_works":[],"abstract_inverted_index":{"Atopic":[0],"dermatitis":[1],"(AD)":[2],"is":[3],"driven":[4],"by":[5],"a":[6,24,30,36,46,65,73,138,145,164,170],"self-perpetuating":[7],"cycle":[8],"of":[9,26,33,83],"immune":[10],"dysregulation":[11],"and":[12],"skin":[13],"barrier":[14],"dysfunction.":[15],"While":[16],"dupilumab":[17,95],"provides":[18],"sustained":[19],"efficacy":[20],"for":[21,68],"moderate-to-severe":[22],"disease,":[23],"subgroup":[25],"patients":[27],"may":[28],"experience":[29],"secondary":[31,139],"loss":[32],"response,":[34],"creating":[35],"therapeutic":[37],"challenge":[38],"due":[39],"to":[40,87,97,109,115,149],"limited":[41],"real-world":[42],"data.":[43],"We":[44],"present":[45],"36-year-old":[47],"male":[48],"with":[49,163],"severe":[50],"upper-body":[51],"AD":[52],"(initial":[53],"BSA":[54],"15%,":[55],"pruritus":[56,78,106,130],"7/10)":[57],"who":[58],"achieved":[59,125],"rapid":[60],"clearance":[61,103,127],"on":[62],"dupilumab,":[63],"maintaining":[64],"stable":[66],"response":[67],"three":[69],"years":[70],"before":[71],"experiencing":[72],"breakthrough":[74],"flare":[75],"(BSA":[76,104,128],"5%,":[77],"6/10).":[79,107],"The":[80],"adjunct":[81],"introduction":[82],"delgocitinib":[84],"cream,":[85],"used":[86],"treat":[88],"chronic":[89],"hand":[90],"eczema":[91],"(CHE),":[92],"alongside":[93],"increased":[94],"frequency":[96],"weekly":[98],"dosing":[99],"yielded":[100],"only":[101],"partial":[102],"2%,":[105],"Due":[108],"incomplete":[110],"resolution,":[111],"the":[112,123],"patient":[113,124],"transitioned":[114],"tralokinumab,":[116],"an":[117],"IL-13":[118,167],"inhibitor.":[119],"After":[120],"12":[121],"weeks,":[122],"complete":[126],"0%,":[129],"0/10).":[131],"This":[132],"clinical":[133],"case":[134],"demonstrates":[135],"that":[136],"managing":[137],"biologic":[140],"failure":[141],"does":[142],"not":[143],"necessitate":[144],"disruptive":[146],"class":[147,162],"switch":[148],"oral":[150],"JAK":[151],"inhibitors,":[152,154],"IL-31":[153],"or":[155],"traditional":[156],"systemic":[157],"immunosuppressants;":[158],"rather,":[159],"staying":[160],"in":[161],"more":[165],"targeted":[166],"inhibitor":[168],"remains":[169],"highly":[171],"effective":[172],"strategy.":[173]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}